Diffusion MRI May Differentiate Primary Progressive From Relapsing Remitting MS
Study researchers assessed the morphometric and microstructural gray matter differences between primary progressive and relapsing remitting multiple sclerosis.
Relapsing Remitting Multiple Sclerosis
Case Study: Herpes Zoster in Patients With MS Treated With Dimethyl Fumarate
This case study examines 2 patients with relapsing remitting multiple sclerosis, under dimethyl fumarate treatment, who developed severe herpes zoster infection.
Contrasting Patterns of Gray Matter Damage Across Subtypes of MS
Investigators strove to quantify imaging patterns of central nervous system damage in MOGAD during the remission stage, and to compare it with NMOSD-AQP4 and MS.
FDA Rejects Aubagio sNDA for Pediatric Relapsing MS Indication
The labeling for Aubagio has been updated to include safety data from the pediatric clinical trial program.
Deficiency of GlcNAc and HexNAc Linked to Progressive MS
Study researchers investigated a marker of endogenous serum N-acetylglucosamine levels in patients with multiple sclerosis.
Novel Ambulatory and Cognitive Biomarkers in Relapsing-Remitting MS
Investigators examined the relationships between morphological and diffusional properties in cerebral gray matter and physical and cognitive performance in patients with relapsing-remitting MS.
COVID-19 Incidence Higher Among Patients With MS Than General Population
Investigators conducted a survey to assess the incidence of COVID-19 in patients with multiple sclerosis as well as the influence of their comorbidities and treatments on outcomes.
Four Possible Indicators of Cognitive Involvement in Early-Stage Multiple Sclerosis
The cognitive effects of multiple sclerosis are often associated with later stages of the disease. However, there may be some indicators of its involvement in patients with early stages. Understanding these factors — some of which are psychological and some of which are clinical — could help with treating and monitoring patients.
A Novel Score Can Identify Patients at Risk for Secondary Progressive MS
A team of researchers assessed the Secondary Progressive Risk Score (SP-RiSc) on its ability to identify patients at elevated risk of secondary progressive MS.
Antibody Response After Vaccination in People With MS Taking MAVENCLAD
Neurology Advisor spoke with Klaus Schmierer, MBBS, PhD, to discuss new evidence suggesting a protective antibody response following vaccination in patients with MS taking MAVENCLAD.
- Loading...
Loading...
Next post in Multiple Sclerosis
Loading... 
Loading...